Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1058810 | 0.81 | SLC9A1 (0.55) | SLC9A1KDM4EKMT2AATAD2 | |
| SCHEMBL26037657 | 0.73 | L3MBTL1 (0.38) | SLC9A1ALDH1A1 | |
| SCHEMBL8656134 | 0.71 | ALDH1A1 (0.47) | SLC9A1ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL28021077 | 0.71 | ATAD2 (0.34) | SLC9A1ALDH1A1ATAD2 | |
| SCHEMBL26034573 | 0.68 | ALDH1A1 (0.35) | ALDH1A1KMT2AMAPT | |
| SCHEMBL8876920 | 0.67 | SLC9A1 (0.53) | SLC9A1ALDH1A1KDM4EKMT2AATAD2 | |
| SCHEMBL15110502 | 0.65 | SLC9A1 (0.51) | SLC9A1HPGD | |
| SCHEMBL4657306 | 0.64 | MAPT (0.42) | ALDH1A1KDM4EKMT2AMAPT | |
| SCHEMBL2153695 | 0.62 | SLC9A1 (0.63) | SLC9A1KDM4EKMT2A | |
| SCHEMBL7643597 | 0.62 | SLC9A1 (0.63) | SLC9A1ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322842-A1 | COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-10806791-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2020-08-13 | — | — | US | disclosed |
| US-20200061097-A1 | RIG-I AGONISTS AND METHODS USING SAME | HOWARD HUGHES MEDICAL INSTITUTE | 2020-02-27 | — | — | US | disclosed |
| US-10550386-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2019-11-14 | — | — | US | disclosed |
| US-20190184018-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2019-06-20 | — | — | US | disclosed |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| CN-103841827-A | Small molecule compounds for controlling plant-and insect-pathogenic nematodes | CALIFORNIA INST OF TECHN | 2014-06-04 | — | — | CN | disclosed |
| US-20050186591-A1 | Method of treating neurodegenerative disease | ALNYLAM PHARMACEUTICALS | 2005-08-25 | — | — | US | disclosed |
| US-20050153337-A1 | iRNA conjugates | ALNYLAM PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| CN-1308684-A | Method for identifying drug action route | ROSETTA INPHARMATICS INC (US) | 2001-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153337-A1 | iRNA conjugates | AGO2, NSUN3, RNASE1 | SLC9A1 3911/4885ALDH1A1 2957/4885KDM4E 2821/4885 |
| US-20190184018-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | SLC2A2, SLC2A8, SLC2A1 | SLC9A1 1892/4885ALDH1A1 2188/4885KDM4E 4549/4885 |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | SLC9A1 4102/4885ALDH1A1 1745/4885KDM4E 4097/4885 |
| US-20050186591-A1 | Method of treating neurodegenerative disease | SNCA, PARK7, NLN | SLC9A1 2731/4885ALDH1A1 1798/4885KDM4E 3524/4885 |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | SLC9A1 4379/4885ALDH1A1 3911/4885KDM4E 3864/4885 |
| US-20230322842-A1 | COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER | NSUN2, RNGTT, NSUN3 | SLC9A1 488/4885ALDH1A1 2051/4885KDM4E 4513/4885 |
| US-10550386-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | FANCI, PCNA, DNMT1 | SLC9A1 4060/4885ALDH1A1 971/4885KDM4E 1948/4885 |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | SLC9A1 4060/4885ALDH1A1 971/4885KDM4E 1948/4885 |
| US-11530408-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | SLC9A1 4379/4885ALDH1A1 3911/4885KDM4E 3864/4885 |
| US-10806791-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | SLC2A2, SLC2A8, SLC2A1 | SLC9A1 1892/4885ALDH1A1 2188/4885KDM4E 4549/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | SLC9A1 4102/4885ALDH1A1 1745/4885KDM4E 4097/4885 |
| US-20200061097-A1 | RIG-I AGONISTS AND METHODS USING SAME | CD274, HAVCR2, MAVS | SLC9A1 4785/4885ALDH1A1 917/4885KDM4E 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.